Randomized Phase II Trial of Sorafenib, Capecitabine and Oxaliplatin (SECOX) versus Single Agent Sorafenib in Patients with Advanced Hepatocellular Carcinoma

View Statistics Email Alert RSS Feed

Grant Data
Project Title
Randomized Phase II Trial of Sorafenib, Capecitabine and Oxaliplatin (SECOX) versus Single Agent Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Principal Investigator
Dr Yau, Thomas Chung Cheung   (Principal Investigator (PI))
Co-Investigator(s)
Professor Cheung Tan To   (Co-Investigator)
Dr Lee Ann Shing   (Co-Investigator)
Dr Cheung Florence   (Co-Investigator)
Duration
30
Start Date
2015-04-01
Amount
626806
Conference Title
Randomized Phase II Trial of Sorafenib, Capecitabine and Oxaliplatin (SECOX) versus Single Agent Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Presentation Title
Keywords
capecitabine, hepatocellular carcinoma, oxaliplatin, sorafenib
Discipline
Cancer
Panel
Biology and Medicine (M)
HKU Project Code
17125414
Grant Type
General Research Fund (GRF)
Funding Year
2014
Status
Completed